GlassScriptPhysician profile
Paige Lindberg
NPI 1467640771
$1,454.68
in general payments reported to CMS, 2019-2025
22 companies · $598 in 2025
The $598 reported for 2025 was more than what a typical Otolaryngology provider received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $77.13 · 2020: $13.73 · 2021: $14.44 · 2023: $336 · 2024: $415 · 2025: $598.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,088 · Education: $262.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,087.56 |
| Education | $261.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $480.08 | 2023-2025 | Dupixent |
| Integra Lifesciences Corporation | $202.84 | 2024 | Acclarent Aera |
| Optinose US, INC. | $123.16 | 2019-2025 | |
| Genzyme Corporation | $112.95 | 2023-2025 | |
| Hikma Pharmaceuticals USA | $61.78 | 2023-2025 | Ryaltris |
| Amgen INC. | $57.65 | 2025 | |
| Glaxosmithkline, LLC. | $46.90 | 2023-2025 | Nucala |
| Alk-Abello, INC | $45.38 | 2023-2025 | Odactra, Ragwitek, Grastek |
| Stryker Corporation | $41.44 | 2019-2023 | Xpress Ent Dilation System |
| Inspire Medical Systems, INC. | $31.47 | 2025 | Inspire |
| Neurent Medical Limited | $29.87 | 2025 | Neuromark Radiofrequency Console, Neuromark System |
| Kerecis Limited | $29.65 | 2023 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Marigen, Kerecis Omega3 Graftguide |
| Microtransponder, INC. | $27.33 | 2023 | |
| Bsn Medical INC | $21.57 | 2025 | |
| Surgenex LLC | $20.68 | 2025 | Surgraft, Pellograft, Surmatrix |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Respicardia, INC. | $20.58 | 2024 | Remede System |
| Astrazeneca Pharmaceuticals LP | $20.56 | 2025 | Tezspire |
| Galderma Laboratories, L.P. | $19.94 | 2019 | |
| Phadia US INC. | $18.63 | 2025 | Immunocap |
| Merck Sharp & Dohme LLC | $18.23 | 2023 | |
| Acera Surgical, INC. | $12.88 | 2023 | Restrata Wound Matrix |
| 3b Medical, INC. | $11.11 | 2023 | Luna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paige Lindberg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.